Athenex Announces $100 Million Private Placement

NEXT STORY
CorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update on May 13
PREV STORY
Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Human Papillomavirus Vaccine Market to reach US$ 3.5 Bn by 2025; Most Promising Indication to Invest in is Cervical Cancer

Albany, NY, March 20, 2018 (GLOBE NEWSWIRE) -- The global human papillomavirus vaccine market ...

author_avatar
NASDAQ Market News

Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma

SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Immune Design ...

author_avatar
NASDAQ Market News

Aptose Enters into $15.5 Million Common Shares Purchase Agreement with Aspire Capital Fund, LLC

SAN DIEGO and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” ...

author_avatar
NASDAQ Market News